CANNABIDIOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H30O2
Molecular Weight	314.4617
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1

InChI

InChIKey=QHMBSVQNZZTUGM-ZWKOTPCHSA-N

InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugabuse.gov/about-nida/legislative-activities/testimony-to-congress/2016/biology-potential-therapeutic-effects-cannabidiol
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline

Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties. Exact mechanism of action of cannabidiol is not known, but may include effects on the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 glycine receptors. GW Pharmaceuticals successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex® (buccal spray containing delta-9-tetrahydrocannabinol and cannabidiol) now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis. GW Pharmaceuticals is developing Epidiolex® (a liquid formulation of pure plant-derived cannabidiol) for certain rare and severe early-onset, drug-resistant epilepsy syndromes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin 1a (5-HT1a) receptor 177 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16258853	Agonist 2752
Vanilloid receptor 53 Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11606325	Agonist 2752	3.2 µM [EC50]
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27754480	Partial Agonist 297	11.0 nM [Ki]
G-protein coupled receptor 55 6 Target ID: CHEMBL1075322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17876302	Antagonist 2849	445.0 nM [IC50]
Glycine receptor subunit alpha-3 10 Target ID: CHEMBL1075092 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22585736	Binding Agent 1076

Conditions

Condition	Modality	Highest Phase	Product
Multiple sclerosis 107 Sources: http://sativex.co.uk/static/media/images/pdf/pil_uk.pdf	Palliative	Approved 8583	SATIVEX Approved Use Sativex is used in multiple sclerosis (MS) to improve symptoms related to muscle stiffness. This is also called “spasticity”. Spasticity means there is an increase in ‘muscle tone’ which makes the muscles feel more stiff or rigid. This means it is more difficult than normal to move the muscle. Sativex is used when other medicines have not helped your muscle stiffness.
Pain 619 Sources: http://omr.bayer.ca/omr/online/sativex-dhcpl-lapds-08-01-2007-en.pdf	Primary	Approved 8583	SATIVEX Approved Use SATIVEX® buccal spray is indicated as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain.
Lennox-Gastaut syndrome 4 Sources: https://www.gwpharm.com/epilepsy-patients-caregivers/patients	Primary	Phase III 665	EPIDIOLEX Approved Use Unknown
Dravet syndrome 5 Sources: https://www.gwpharm.com/epilepsy-patients-caregivers/patients	Primary	Phase III 665	EPIDIOLEX Approved Use Unknown
Tuberous sclerosis complex 1 Sources: https://www.gwpharm.com/epilepsy-patients-caregivers/patients	Primary	Phase III 665	EPIDIOLEX Approved Use Unknown

C_max

Value	Dose	Analyte	Population
292.4 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
782 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1588 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
327 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
330.3 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
541.2 ng/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1618 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3900 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8670 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2198 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1745 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3236 ng × h/mL OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
14.43 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.42 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
56.41 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60.54 h OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
6% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered:		CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6% OTHER GOV https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf	6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered:		CANNABIDIOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	inhibitor 2438		inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B3 961 CYP2C19 2057 CYP1A2 2153 CYP2B6 926 CYP2C8 1057 UGT1A9 148 UGT2B7 197 P-gp 1741 OAT1 725 OAT3 747 OCT2 779 MATE1 415 MATE2 267 OATP1B1 1079 BSEP 550 OCT1 620 BCRP 910	CYP2C19 1119 UGT1A7 249 UGT1A9 423 UGT2B7 456 P-gp 2052 OATP1B1 503 OATP1B3 435 BCRP 697	CYP1A2 832 CYP2B6 669

Drug as perpetrator

Target	Modality	Activity	Metabolite
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
MATE2 267	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OCT1 656	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-OH-CBD 1
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=13 Page: 13.0	yes
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
UGT1A9 155	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes
UGT2B7 210	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no	7-COOH-CBD 1
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=21 Page: 21.0	no
UGT1A7 249	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes
UGT1A9 423	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes
UGT2B7 456	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes		likely Comment: Co-administration with moderate or strong inhibitors of CYP3A4 or CYP2C19 is predicted to increase CBD plasma concentrations which may increase the risk CBD toxicities. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0	yes		likely Comment: Co-administration with moderate or strong inhibitors of CYP3A4 or CYP2C19 is predicted to increase CBD plasma concentrations which may increase the risk CBD toxicities. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000ClinPharmR.pdf#page=7 Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf#page=20 Page: 20.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:69478	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:69478
ChemicalBook	CB7673434	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7673434
eMolecules	536311	https://www.emolecules.com/cgi-bin/more?vid=536311
ZINC	ZINC000004097406	http://zinc15.docking.org/substances/ZINC000004097406

PubMed

Title	Date	PubMed
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.	2003	12952500
Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats.	2003 Apr-Jun	14527182
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.	2003 Aug	12899667
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors.	2003 Aug 8	12921861
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?	2003 Dec	14738597
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model.	2003 Dec 12	14644587
Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils.	2003 Jul 31	12850548
Gateways to clinical trials.	2003 Jun	12851663
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite.	2003 Nov	14578199
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current.	2003 Nov 14	12952947
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.	2003 Nov 8	14615106
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?	2003 Nov 8	14615102
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells.	2003 Oct	14692532
Neuroscience. Stout guards of the central nervous system.	2003 Oct 3	14526067
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.	2004 Apr	15030397
Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.	2004 Apr 5	15063151
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.	2004 Aug	15327041
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats.	2004 Dec	15567426
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.	2004 Dec	15561385
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain.	2004 Feb	14984418
Effects of cannabidiol (CBD) on regional cerebral blood flow.	2004 Feb	14583744
Determination of cannabinoids in hemp food products by use of headspace solid-phase microextraction and gas chromatography-mass spectrometry.	2004 Jan	14598006
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).	2004 Jan	13680081
Medicinal cannabis extracts for the treatment of multiple sclerosis.	2004 Jul	15298068
A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).	2004 Jul	14740147
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.	2004 Jul 15	15239658
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.	2004 Jun	15118485
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum.	2004 Jun 18	15158372
Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol.	2004 Mar	15025853
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.	2004 Mar	15022343
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.	2004 Mar	14963641
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.	2004 Mar	14617682
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.	2004 Mar 8	15033394
Cannabinoids in hair: strategy to prove marijuana/hashish consumption.	2004 Oct 29	15451086
Cannabis (marijuana) contamination of United States and foreign paper currency.	2004 Sep	15516293
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.	2004 Sep	15313881
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice.	2005 Apr 11	15840405
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity.	2005 Aug	15878999
Gene ancestry of the cannabinoid receptor family.	2005 Dec	16118055
A rapid and simple procedure for the determination of cannabinoids in hemp food products by gas chromatography-mass spectrometry.	2005 Jan 4	15620517
The use of cannabinoids in multiple sclerosis.	2005 Jul	16022575
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens.	2005 Jun	15910889
Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.	2005 Jun	15910887
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.	2005 Jun-Jul	15837565
Effect of cannabis use in human brain activity.	2005 Mar	15867974
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.	2005 May	15888515
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.	2005 May	15845890
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids.	2005 Sep	16148455
Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits.	2005 Sep	15955678
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.	2006 Apr	16052245

Patents

Sample Use Guides

In Vivo Use Guide

SATIVEX® is provided as a buccal spray in a 5.5 ml vial, with each 100 microlitre spray providing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). In patients with multiple sclerosis, the median daily dosage of SATIVEX® in the extension phase of the 4-week clinical trial was 5 sprays per day. The majority of patients required 12 sprays or less; dosage should be adjusted as needed and tolerated. There is limited experience with doses higher than 12 sprays per day. Some patients may require and may tolerate a higher number of sprays. In patients with pain in cancer, the median daily dosage of SATIVEX® was 8 actuations (sprays).

Route of Administration: Topical

In Vitro Use Guide

in vitro pre-treatment of Human Gingival Mesenchymal Stem Cells with 5 uM Cannabidiol (CBD) can influence their expression profile

Name

Type

Language

CANNABIDIOL

Official Name

English

cannabidiol [INN]

Preferred Name

English

CANNABIDIOL [USAN]

Common Name

English

CANNABIDIOL [USP-RS]

Common Name

English

.DELTA.1(2)-TRANS-CANNABIDIOL

Common Name

English

Cannabidiol [WHO-DD]

Common Name

English

(-)-CANNABIDIOL

Common Name

English

EPIDIOLEX

Brand Name

English

CANNABIDIOL [MART.]

Common Name

English

CARDIOLRX

Brand Name

English

2-((1R,6R)-3-METHYL-6-(PROP-1-EN-2-YL)CYCLOHEX-2-EN-1-YL)-5-PENTYLBENZENE-1,3-DIOL

Systematic Name

English

2-((1R,6R)-3-METHYL-6-(1-METHYLETHENYL)CYCLOHEX-2-ENYL)-5-PENTYLBENZENE-1,3-DIOL

Systematic Name

English

BTX-1503

Code

English

(-)-CBD

Common Name

English

GWP-42003

Code

English

CANNABIDIOL [MI]

Common Name

English

CBD

Common Name

English

BTX-1204

Code

English

CANNABIDIOL [ORANGE BOOK]

Common Name

English

1,3-BENZENEDIOL, 2-((1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL)-5-PENTYL-

Systematic Name

English

CANNABIDIOL SOLUTION [USP-RS]

Common Name

English

GWP-42003-P

Code

English

GWP42003

Code

English

(-)-TRANS-CANNABIDIOL

Common Name

English

GWP42003-P

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/17/1959